Brief: Polyphor Receives Up To USD 3.3 Million To Develop Murepavadin

Spexis AG

24/11/2020 06:32

Nov 24 (Reuters) - POLYPHOR AG  POLN.S :
    * RECEIVES AWARD OF UP TO USD 3.3 MILLION FROM CYSTIC
FIBROSIS
FOUNDATION TO SUPPORT CLINICAL DEVELOPMENT OF INHALED ANTIBIOTIC
MUREPAVADIN
    * AWARD WILL HELP TO FUND PLANNED PHASE IB/IIA STUDY OF
INHALED
MUREPAVADIN, A NOVEL CLASS ANTIBIOTIC FOR TREATMENT OF CHRONIC
PSEUDOMONAS AERUGINOSA INFECTIONS IN CYSTIC FIBROSIS
    * DEVELOPMENT PROGRAM IS CURRENTLY JOINTLY FUNDED BY
POLYPHOR AND
EUROPEAN INNOVATIVE MEDICINES INITIATIVE (IMI) UNTIL END OF
PLANNED PHASE IA STUDY

Source text for Eikon:  ID:nEQ6Kvyp5a 
Further company coverage:  POLN.S 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))